Foundation Medicine, Inc., a leader in precision medicine transforming cancer care, has announced a strategic partnership with Manifold, the leading artificial intelligence (AI) data platform for life sciences, to enhance its FoundationInsights® platform with advanced AI-powered analytics. The collaboration aims to accelerate drug discovery and development by enabling biopharmaceutical partners to extract deeper, faster insights from one of the largest real-world datasets in oncology. FoundationInsights®, a cloud-based analytics and visualization platform, now integrates Manifold’s AI capabilities, allowing users to leverage natural language queries to quickly identify patient cohorts or explore the prevalence of specific genomic alterations. The upgraded platform supports complex genomic criteria through intuitive, conversational search, while also offering technical users the ability to conduct in-depth, customized analyses using popular programming languages like Python and R. The enhanced version of FoundationInsights® provides access to Foundation Medicine’s proprietary multimodal dataset, which includes de-identified genomic data from more than 800,000 patients. This rich, real-world evidence base is critical for identifying potential drug targets, understanding treatment response patterns, and designing more effective clinical trials. “Foundation Medicine is using AI and machine learning to power our real-world data solutions to accelerate drug discovery and development,” said Troy Schurr, Chief Biopharma Business Officer at Foundation Medicine. “With new AI-powered capabilities from Manifold, biopharmaceutical partners can find the answers they need to make decisions faster than ever before. Our partners now have a one-stop shop to access comprehensive multimodal data from Foundation Medicine, combined with advanced analytics and visualization tools—so patients can benefit from advances in precision medicine sooner.” Vinay Seth Mohta, CEO and co-founder of Manifold, highlighted the strategic alignment between the two companies. “Foundation Medicine is a pioneer in precision diagnostics,” Mohta said. “By combining Foundation Medicine’s powerful multimodal databases with Manifold’s purpose-built AI capabilities for life sciences, we can make it easier for researchers to work smarter and faster to unlock the answers needed to discover innovative personalized therapies.” The AI-enhanced FoundationInsights® is now available to biopharmaceutical partners. A customized version for healthcare providers and health systems is scheduled for launch in 2026, expanding access to clinical insights that can inform patient care and population health strategies. Foundation Medicine continues to advance its mission of transforming lives in cancer and beyond by delivering multi-modal precision diagnostic solutions across the patient journey—from pre-diagnosis to ongoing monitoring. Through partnerships like this one, the company strengthens its role in accelerating the development of personalized therapies for cancer and other diseases. Manifold, the leading AI data platform for life sciences, is widely adopted by top research institutions and global biopharma organizations. By integrating with platforms like Terra and collaborating with technology leaders such as AWS and Anthropic, Manifold is enabling faster, more collaborative, and governed analysis of complex biomedical data—turning months of work into minutes. For more information about FoundationInsights®, visit https://www.foundationmedicine.com/foundation.insights. Foundation Medicine® and FoundationInsights® are registered trademarks of Foundation Medicine, Inc. Manifold and Manifold AI are trademarks of Manifold Inc.